AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
12 août 2024 16h05 HE
|
AEON Biopharma
– Progressing plans to develop ABP-450 (prabotulinumtoxinA) injection as a biosimilar utilizing BOTOX® (onabotulinumtoxinA) as the reference product – – Scheduled to hold a biosimilar initial...
AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450
09 juil. 2024 08h00 HE
|
AEON Biopharma
– Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the 351(k) pathway following an in-person FDA meeting scheduled for Q3 2024 – IRVINE, Calif.,...
AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan
29 mai 2024 08h00 HE
|
AEON Biopharma
IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum...
AEON Biopharma Reports First Quarter 2024 Financial Results
14 mai 2024 16h05 HE
|
AEON Biopharma
– Ongoing analysis of interim data from the Phase 2 study of ABP-450 in chronic migraine, which did not achieve its primary or secondary endpoints – – Evaluating next-steps across the Company’s...
AEON Biopharma Provides Update on Development Pipeline
09 mai 2024 08h00 HE
|
AEON Biopharma
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum...
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
03 mai 2024 07h00 HE
|
AEON Biopharma
IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum...
CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants
30 mars 2024 22h53 HE
|
AEON Biopharma
IRVINE, Calif., March 30, 2024 (GLOBE NEWSWIRE) -- Regarding a release issued under the same headline on March 29, 2024 by AEON Biopharma, Inc. (NYSE: AEON; AEON.WS), please note that in the first...
AEON Biopharma Announces Redemption of Public Warrants
29 mars 2024 16h15 HE
|
AEON Biopharma
IRVINE, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON; AEON.WS) (“AEON” or “the Company”), a clinical-stage biopharmaceutical company focused on developing a...
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results
29 mars 2024 15h45 HE
|
AEON Biopharma
– Recent end-of-Phase 2 meeting with FDA resulted in alignment on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine – ...
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine
19 mars 2024 16h30 HE
|
AEON Biopharma
– FDA and AEON align on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine – – An interim analysis from the ongoing...